Immunotherapy for Head and Neck Cancer in the Era of Exponentially Increasing Health Care Expenditure

Abstract

The FDA-approved immune checkpoint inhibitors, nivolumab and pembrolizumab, are the most recent biological therapies in the therapeutic armamentarium for recurrent metastatic head and neck squamous cell carcinomas. This article highlights the tools for analyzing the costeffectiveness of such therapies.